No-Implant Interatrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Six-Month Outcomes From Multi-Center Pilot Feasibility Studies
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Consultant Fee/Honoraria/Speaker's Bureau - Bayer AG; Cardurion; Alleviant; Reprieve CV
- Grant Support/Research Contract - LivaNova; Abiomed; Medtronic